spacer
home > ebr > winter 2009 > streamlining processes
PUBLICATIONS
European Biopharmaceutical Review

Streamlining Processes

Procurement officers, lab managers and CFOs at pharmaceutical and biopharmaceutical companies are under tremendous pressure to improve internal processes, outsource internal functions and focus on suppliers’ costs. They have traditionally relied on original equipment manufacturers (OEMs) to maintain their vast and diverse range of laboratory equipment and inventories. This is fine if there are only a small number of assets, but the majority of biopharmaceutical companies have hundreds of assets, each requiring individual maintenance contracts.

Furthermore, there are a number of disadvantages to this model, including the administrative burden on employees (and hence the detraction from normal work), and the time it takes to manage vast inventories, which can divert resources away from core scientific projects.

One way to improve asset management efficiency and drive down costs is to use an external multi-vendor asset management service to maintain all laboratory equipment and inventory. Such third-party service providers can offer a wide range of services, including:


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Bob Moore is the North American Service Sales Director for GE Healthcare’s Life Sciences business. Bob started his career with GE in 1986. His vast service experience with GE Healthcare began as a field engineer, and he has spent the last few years in developing and marketing GE’s service offerings and business solutions for the life science markets. Bob holds a BS EET degree from DeVry Technical Institute in Chicago, IL. Bob has also received extensive leadership training at the John F. Welch Leadership Training Center in Crotonville, NY.
spacer
Bob Moore
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Shionogi, Active Citizenship Network and Meps Advocate for Urgent Policy Implementation in Eu Member States at Eu Parliament Event to Address the Growing Threat of Antimicrobial Resistance

OSAKA, Japan and AMSTERDAM, NL, 28 November 2022 – Shionogi & Co., Ltd. and its European subsidiary, Shionogi B.V. (hereafter "Shionogi"), held an event at the EU Parliament last week in the run-up to World Antimicrobial Awareness Week, joining forces with MEPs, Active Citizenship Network and MEPs Interest Group on "European Patients' Rights & Cross-Border Healthcare" to discuss initiatives to tackle AMR. The event reinforced the need for urgent attention and collaboration from pharmaceutical companies, policy stakeholders and governments to bring about policy change and innovation to address this growing issue.
More info >>

White Papers

Advanced BioDesign Outlines Solutions

Advanced BioDesign

Launching an immunisation programme is an important experimental step that needs care. With Advanced BioDesign, clients may develop and produce antibodies according to customers' specific needs. The company offers: real support and advice from a dedicated team all along your project; large and modern SPF animal facility; ethical treatment of animals. The evaluation of a project is free-of-charge and with no obligation. Dedicated project managers will work with clients from the beginning to the end of a custom antibody project to ensure the highest level of quality and service.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement